Results 31 to 40 of about 27,196 (258)
mAbs, 2021 Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with two different heavy chains is greatly simplified if the light chains can be the ...
Kathryn H. Ching +7 more
doaj +1 more source
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Life, 2021 Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen +2 more
doaj +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
Antibodies, 2019 In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang +10 more
doaj +1 more source
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Frontiers in Immunology, 2023 The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia +24 more
doaj +1 more source
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
Molecular Therapy: Methods & Clinical Development, 2017 Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse +6 more
doaj +1 more source
mAbs, 2020 The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang +17 more
doaj +1 more source
Engineering a novel IgG-like bispecific antibody against enterovirus A71
Biochemistry and Biophysics Reports, 2020 Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang +7 more
doaj +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Current Opinion in Biotechnology, 2020 Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire +2 more sources
Bispecific antibodies in cancer immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2016 Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen +3 more
openaire +2 more sources